Louisiana picks drug company for hepatitis C treatment plan - (The Miami Herald via NewsPoints Desk)

  • Gilead Sciences' Asegua Therapeutics unit has won a contract to provide Louisiana's Medicaid recipients and prisoners with broad access to hepatitis C treatments under a subscription-style model, as reported Miami Herald Tuesday.

  • Under the agreement, the state will receive unlimited access to Epclusa for five years for a flat annual fee.

  • Louisiana Health Secretary Rebekah Gee said the agreement offers "a clear path forward to offer a hepatitis C cure to our most vulnerable patients," adding that the contract will likely go into force July 1.

  • The state had estimated that a per-patient model would cost the state $760 million.

  • Asegua representative Gregg Alton, who described the model as "groundbreaking," stated "this is an important step forward on the path to eliminating the virus in Louisiana."

  • FirstWord Reports: Providing insight, analysis and expert opinion on important Pharma trends and challenging issues <Click here>

To read more NewsPoints articles, click here.